1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Cancer Cachexia Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Cancer Cachexia Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • March 2021
  • 154 pages
  • ID: 6028491
  • Format: PDF
  • Mordor Intelligence LLP
Up to $750 off Until Apr 20th 2021


Table of Contents

Search Inside

The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period.

The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced globally. The COVID-19 pandemic also affected the global economy and showed a huge impact on the general hospital care functioning for non-COVID-19 patients in hospitals across the world.

According to the research article published in the British Journal of Nutrition, 2020, changes in the nutritional status and weight loss during hospitalization are largely reported in some populations, but it is not completely explored in COVID-19 patients. However, the symptoms and associated conditions of COVID-19 leads to nutritional status deterioration, leading to cachexia.

Also, cancer patients are at a higher risk of being infected with COVID-19, as cancer patients are immunocompromised and their ability to fight against the infection is very low compared to other individuals. Additionally, if a cancer patient develops a COVID-19 infection, there are higher chances of developing multiple organ-related complications or cachexia.

The increasing prevalence of cancer and cancer cachexia cases, along with the increasing investment in the research and development activities for the development of novel therapeutics in the treatment of cancer cachexia, are the major factors driving the market growth.

The global cancer burden is increasing, so cancer therapies must be modified according to regional and national priorities. As per the International Agency for Research on Cancer (IARC in December 2020, estimated that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. Hence, the increasing burden of cancers worldwide also increases the prevalence of cancer cachexia among cancer patients, which is characterized by systemic inflammation, negative protein and energy balance, and an involuntary loss of lean body mass.

Because of this factor, most of the major players are focused on R&D activities for the development of highly effective novel drugs in the treatment of cancer cachexia. This resulted in an increased pipeline of therapeutics that are waiting for approval and commercial launch post-approval. For instance, ClinicalTrials.gov reported that as of December 2020, there were a total of 134 studies that were conducted or were being conducted to develop drugs that treat cancer cachexia.

However, manufacturers of cancer cachexia drugs are discouraged from investing in the market because of the strict regulatory requirements and the long FDA approval procedure, which may impede the long-term growth of this market.

Key Market Trends
Appetite Stimulators is Expected to Grow Significantly in the Global Cancer Cachexia Market

Cancer patients frequently develop loss of appetite and weight loss. Unintended weight loss and anorexia (the loss of appetite or desire to eat) in patients with cancer is associated with decreased performance status, reduced response and tolerance to treatment, decreased survival, and reduced quality of life. Therefore, the increasing use of an appetite stimulant could be considered for patients who exhibit decreased appetite. The increasing prevalence of cancer cachexia cases is one of the major factors propelling the overall market’s growth.

According to the Oncology Nursing Society, appetite stimulants, such as dexamethasone, methylprednisolone, prednisolone, megestrol acetate, and medroxyprogesterone acetate, have been shown to increase the appetite and weight of patients suffering from cancer cachexia. Megestrol acetate is an appetite stimulant with progestational and antigonadotropic effects. In cancer patients with weight loss, megestrol acetate has been reported to have beneficial effects on appetite and results in a slight increase in weight, but it has not produced improvements in lean body mass or quality of life. Thus, their demand is expected to increase with the increase in the diagnosis of cancers.

Therefore, with the growing burden of cancer across the world, market players are investing steadily in innovative products and their R&D, which boosts the market growth.

For instance, in March 2020, Pfizer Inc., a global pharmaceutical major, launched a global 12-week open-label study which will explore how its drug PF-06946860 is tolerated in patients with cancer cachexia. Hence the factors mentioned above, helps the appetite stimulators segment is anticipated to achieve a high growth rate in the future.

North America is Expected to Dominate the Cancer Cachexia Market

North American is expected to dominate the market due to the high burden of cancer and cancer cachexia along with the presence of a large number of drug manufacturers and the advancing paradigm of care for cancer patients that is supporting the growth in this region. According to the estimates of Globocan 2020, there are around 195,499 new cases of cancer in Mexico. At the same time, approximately 90,222 deaths were recorded due to cancer in 2020 in Mexico.

According to Markus S. Anker, in the article Orphan disease status of cancer cachexia in the USA and the European Union: a systematic review’, published in 2019, in the 14 separately analyzed cancer types, the prevalence of cancer cachexia in the United States ranged between 11,300 (0.4/10 000, gastric cancer) and 92,000 patients (2.9/10000, lung cancer).

Advancements in novel technology for the treatment of cancer cachexia and a strong product pipeline for wasting syndrome have also helped in the growth of the cancer cachexia market in the region. Aveo Oncology, a United States-based biopharmaceutical company has developed AV-380, its first-in-class, potent, and humanized inhibitory antibody targeting GDF15, for the treatment of cancer cachexia, which is on track for IND application submission, with a planned Phase 1 clinical study for the first quarter of 2021.

Competitive Landscape
The majority of the cancer cachexia therapy drugs are being manufactured by a few key players. Some of the major players include Pfizer Inc., Merck & Co. Inc., Alder BioPharmaceuticals Inc., Aeterna Zentaris, and Bristol-Myers Squibb Company. Product launches, acquisitions, and R&D activities are key strategies adopted by players in the cancer cachexia market. Market leaders with more funds for research and a better distribution system have established their position in the market. For instance, A clinical study on the effect of medical Cannabidiol on lean body mass (cachexia) in patients receiving Oxaliplatin- or Paclitaxel-based chemotherapy was initiated by the University of Copenhagen, in collaboration with Zealand University Hospital, in December 2020.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Veterinary Pain Management Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • $ 4250
  • March 2021
  • 131 pages

The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The ...

  • World
  • Europe
  • Therapy
  • Analgesic
  • Industry analysis
  • Livestock Production
  • Health Expenditure


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on